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Abstract
Childhood cancer survivors face risks from a variety of late effects, including cardiac events, second cancers, and late
mortality. The aim of the pan-European PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies
(PanCareSurFup) Consortium was to collect data on incidence and risk factors for these late effects among childhood
cancer survivors in Europe. This paper describes the methodology of the data collection for the overall PanCareSurFup
cohort and the outcome-related cohorts. In PanCareSurFup 13 data providers from 12 countries delivered data to the data
centre in Mainz. Data providers used a single variable list that covered all three outcomes. After validity and plausibility
checks data was provided to the outcome-specific working groups. In total, we collected data on 115,596 patients diag-
nosed with cancer from 1940 to 2011, of whom 83,333 had survived 5 years or more. Due to the eligibility criteria and
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other requirements different numbers of survivors were eligible for the analysis of each of the outcomes. Thus, 1014
patients with at least one cardiac event were identified from a cohort of 39,152 5-year survivors; for second cancers 3995
survivors developed at least one second cancer from a cohort of 71,494 individuals, and from the late mortality cohort of
79,441 who had survived at least 5 years, 9247 died subsequently. Through the close cooperation of many European
countries and the establishment of one central data collection and harmonising centre, the project succeeded in generating
the largest cohort of children with cancer to date.
Keywords European Cohort · Childhood and adolescent cancer · 5-Year survivors · Late effects · Follow-up ·
Epidemiology
Introduction
Cancer in childhood is rare: for every child who contracts
cancer more than 100 adults get cancer. The overall age-
standardised incidence rate in Europe is 140 cases per mil-
lion children aged 0–14 [1]. Currently, 80% of children
diagnosed in developed countries survive to at least 5 years
[2]. Unlike survivors of adult cancer survivors of childhood
cancer have their whole adult lives ahead of them. The
growing numbers of survivors bring increasing concern
about the long-term consequences of treatment to growing
organs and tissues. Each year there are approximately 35,000
new cases of cancer in young people in Europe and 1 out of
300 new-borns will develop cancer before their 20th birthday
[3]. At present hundreds of thousands of EU citizens have
survived cancer in childhood or adolescence. It is estimated
that this number will reach nearly 500,000 by 2020 [3]. At
least two-thirds will have late effects caused by cancer
treatment [4, 5]. In Europe, several childhood cancer-related
survivor cohorts exist or are in the process of becoming
established [6]. To work to achieve equity of access to care
for childhood cancer survivors across Europe and to perform
collaborative research PanCare—the Pan-European Net-
work for Care of Survivors after Childhood and Adolescent
Cancer—was founded in Lund, Sweden, in 2008. PanCare
became a legal entity in 2013 and was granted charita-
ble status in 2014 in the Netherlands [7]. PanCare (www.
pancare.eu) is a multidisciplinary network of professionals,
survivors and their families.
As part of PanCare the EU funded project PanCare-
SurFup (PanCare Childhood and Adolescent Cancer Sur-
vivor Care and Follow-Up Studies; www.pancaresurfup.eu)
started in 2011 as a cooperation of 16 partners [7] and was
formally completed at the end of January 2017. Within
PanCareSurFup (PCSF) not only partners who are funded
via the EU but also a number of additional data providers
(DPs) have collected data on type of cancer, cancer treat-
ment and the occurrence of complications of cancer treat-
ments in order to create a retrospective European cohort of
more than 100,000 former childhood cancer patients. This
cohort formed the basis for all the analyses carried out in
the working groups of the project [7]. The work package
(WP) structure was as follows: WP1 for data collection and
harmonisation of data, WP2 for to collect radiation therapy
data and reconstruct radiation doses to selected organs and
anatomical sites, WP3 for cardiac disease, WP4 for second
cancers, and WP5 for late mortality. Table 1 describes
WP1 and the outcome-related work packages, WP2 to 5.
The methodology for the data collection for case–control
selection will be described elsewhere.
In this paper we describe the tasks and methods to
establish the overall cohort of 12 European countries that
formed the basis for all PanCareSurFup analyses and
reports. The overall cohort of survivors will be described.
Methods
Data flow of data sets from 12 countries
to establish the PCSF cohort
The basic cohort of survivors was established by WP1 at
the University Medical Center in Mainz, Germany. WP1
had several tasks, e.g. (a) to establish the retrospective pan-
European cohort of long-term survivors in whom one, or
more, of the relevant endpoints occurred: cardiac disease,
second cancer, late mortality, and (b) to provide data sets
for “outcome-related work packages” dealing with these
three endpoints for the cohort studies. The methods of WP1
are reported in this paper including data flow of data sets
from 12 countries to establish the PCSF cohort, setting up
the study protocol and the variable list, the requirements of
the call-for-data and process of data transfer, the strategy
for data protection, safety and security, and data cleaning
and validity checks.
In PanCareSurFup 13 DPs from 12 countries delivered
data: France, Hungary, Italy (a hospital-based and a
18 Norwegian Cancer Register Department of Pediatric
Medicine, Faculty of Medicine, Oslo University Hospital and
Institute of Clinical Medicine, University of Oslo, Oslo,
Norway
19 Division of Radiotherapy, Institute of Oncology, Zalosˇka
cesta 2, 1000 Ljubljana, Slovenia
D. Grabow et al.
123
population-based data set), the Netherlands, the Nordic
Countries (Denmark, Finland, Iceland, Sweden, and Nor-
way), Slovenia, Switzerland, and the UK (Table 2). Those
DPs were either population-based cancer registry cohorts,
5-year survivor cohorts, or national clinical databases with
broad coverage. Italy was an exception with two different
kinds of DPs, providing data of a population-based and a
clinical database setting.
DPs were identified by a survey carried out by PanCare
specifically for the PCSF grant application. So DPs had to
fulfil specific prerequisites: (a) be able to return to the
treating clinic and collect original therapy data, (b) be able
to perform comprehensive follow-up of the individual
survivor, and (c) capture information about at least one of
the following events: prevalent cardiac events or prospec-
tive cardiac adverse events in the follow-up of the patients,
second primaries, and about vital status and for deceased
patients the date and cause of death, encoded in compliance
with international classification systems.
The data flow within PanCareSurFup regarding estab-
lishment of the PCSF cohort and provision of data sets for
the three outcome-related work packages 3–5 is shown in
Fig. 1.
At a later stage of the project WP3 and WP4 had also to
contact DPs directly, e.g. to collect details of radiotherapy
and chemotherapy from the original treatment centres for
the case control selection. No DP could start data collection
until they received ethical approval from their ethics board
within each participating country, in accordance to national
laws and requirements. Additionally, an Ethical and Sci-
entific Advisory Board was set up at the start of PCSF to
support and guide the project.
Study protocol and variable list
The participants developed the study protocol and a list of
common variables. The PCSF variable list was based on
variables that were already available in the databases of all
DPs and could be retrieved and delivered to WP1. It was
critical to establish and maintain the same standards for
each WP, e.g. the list of variables was arranged particularly
with regard to the three outcomes mentioned above and the
same set of standards were kept for each outcome. One of
the main tasks consisted in harmonising baseline variables
to make them suitable for all the different study objectives.
Therefore the project team early on agreed on a common
Table 1 Collection of data for the PanCareSurFup cohort: work packages (WP) 1–5 in PanCareSurFup: title, leader and selected objectives
WP1: Data Collection and Harmonisation (D. Grabow/P. Kaatsch, Mainz, Germany)
Establish the retrospective pan-European cohort of long-term survivors in whom one, or more, of the relevant endpoints occurred: cardiac
disease, second cancer, late mortality
Provide data sets for outcome-related work packages dealing with these three endpoints
WP2: Radiation Dosimetry (F. de Vathaire, Villejuif, France)
Perform radiation therapy reconstruction and whole body dosimetry for the subjects included in WP3 and WP4 who received radiotherapy
Estimate radiation dose received to the heart during radiotherapy, as well as uncertainties in this estimate for WP3 patients
Estimate radiation dose received to the specific site of the second malignant neoplasm during radiotherapy, as well as uncertainties in this
estimate for WP4 patients
WP3: Cardiac disease: cohort and nested case–control study (L. Kremer, Amsterdam, the Netherlands)
Establish a pan-European cohort of survivors of childhood cancer for whom the occurrence of cardiovascular disease has been systematically
ascertained and validated in 5 years childhood cancer survivors (cases graded according the CTCAE v3 criteria; http://ctep.cancer.gov)
Determine the incidence and absolute risk of cardiovascular disease
Undertake a nested case–control study to determine aspects of radiotherapy and chemotherapy associated with increased risk of cardiac
disease
WP4: Subsequent primary neoplasms: cohort and nested case–control studies (M. Hawkins, Birmingham, UK)
Compare observed and expected numbers of second primary cancers (sarcomas of bone and soft tissue and carcinomas of digestive tract and
genito-urinary organs), particularly among survivors who are aged over 40 years
Undertake a nested case–control study of subsequent primary sarcomas and subsequent primary “adult-type” carcinomas as these are the
most frequently observed within the cohort
Undertake those nested case–control studies to determine aspects of radiotherapy and chemotherapy most strongly associated with these
subsequent primary neoplasms
WP5: Late mortality (S. Garwicz, Lund, Sweden)
Establish a pan-European cohort of survivors for which all deaths occurring at least 5 years after diagnosis and for which an official cause of
death is available
Relate absolute and excess risk (compared to background population) of death from specific causes to gender, type of childhood cancer, age
at diagnosis, period of cancer diagnosis and, in a subset of patients, type of treatment
Validate the official causes of death and assess the comparability and quality of causes of death in different countries
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set of variables. This made the work of the DPs easier as
they could deliver their data for different work packages in
a standard format with a common set of variables. Among
others the list of 74 variables concerned the following:
● cardiac disease (13 variables): e.g. specification of all
cardiac events, dates of cardiac events, dates of entry
and exit from risk for cardiac disease. Cardiac events
are namely symptomatic heart failure, cardiac ischemia,
pericarditis, valvular disease and arrhythmia graded
according to the Criteria for Adverse Events (CTCAE)
[8]. More details are described in [9].
● second cancer (15 variables): e.g. number of subsequent
tumours, type of each of second cancers by site,
behaviour dates of entry and exit from risk for second
cancer. Second cancers had to be histologically different
from the first primary neoplasm and to have a malignant
behaviour code. For further details see [10, 11].
● follow-up and death (18 variables): e.g. year of latest
follow-up in relation to vital status, date of death,
underlying and contributing causes of death. Causes of
death were classified according to different versions of
ICD6 to ICD10. An algorithm was developed to group
all the causes of death into 14 categories. For the
category “neoplasms”, patients who had more than one
neoplasm registered were—at default—considered to
have died from a subsequent neoplasm. To validate this
assumption, data were manually scrutinized and if
information was sufficient to deem that the patient
actually died from the primary neoplasm, the classifi-
cation was changed. In cases that remained unclear, this
was clarified in a dialogue with data providers. Finally,
the categories of causes of death were aggregated into
several groups such as primary neoplasm, subsequent
neoplasm, infection, circulatory causes, external causes,
and other causes. A publication is under preparation.
This scheme of variables (available upon request)
enabled a precise description of relevant data from each
European country. Additionally, an exchange of data
between the outcome-related work packages was possible
since they had the same data structure. For instance, when
the cause of death was either cardiac disease or second
cancer a linkage from WP5 to WP3 and WP4 was possible.
Call-for-data, data transfer and data safety
and security
After the variable list and the common study protocol was
agreed WP1 prepared and sent a formal “call-for-data”.
The call-for-data specified rules regarding form and content
PCSF
Study Data base
Data Provider 1
Data Provider 13 
Work Package 3
Work Package 4
Work Package 5
Work Package 1
Plausibility 
Checks
Pre-
check of 
the data
Preparaon 
of Cohort 
Data
Queries
Queries/Quesons/
Decisions
Prepare 
Updates
…
5
2 8
1
4
3 6
7
Fig. 1 Data flow between data provider, central work package WP1
(with its PanCareSurFup study database) and three outcome-related
work packages 3–5 (1: DPs delivered data; 2: WP1 checked technical
quality; 3: WP1 ran plausibility checks; 4: queries to DPs to clarify
implausibility; 5: DPs sent corrected data set; 6: WP1 prepared WP-
specific cohorts; 7: WP1 makes WP-specific cohorts available; 8: WP
sent queries to WP1)
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of the data delivery, set out procedures to ensure data privacy
and safety and set deadlines. Data delivery commenced at 8
May 2012 and ended on 31 December 2015. The results
regarding the PanCareSurFup cohort presented here are
based on the data set frozen on the 11th January 2016.
The transfer of data between DP, WP1, and outcome-
related WPs as well as the entire data processing in WP1
was carried out without identifying information about any
individual. Another measure to protect the data was that
data are exclusively transferred in encrypted form. A multi-
stage security concept was designed to meet modern
standards for data security and data safety to the highest
degree.
Data cleaning and validity checks
All data delivered from DPs were imported in a study
database at WP1´s site. A plausibility check concept was
developed. Checks were programmed with SAS 9.4 [12]
and included more than 150 single check procedures.
Checks dealt with the original data files delivered by the
DPs (Fig. 1, step 1). In a more technical step (step 2) data
were transformed in a suitable data format, which meant e.
g. to restructure a wide format into different outcome
related data packages and imported by VBA programmes
procedures (Visual Basics for Applications, which are part
of the Windows office package). The third step included
checks for plausibility and validity regarding
● identification variables (unique numerical values iden-
tifying individuals within PanCareSurFup)
● valid coding (categorical variables), plausible values,
proper use of the defined missing values and NULL
fields
● cross-checks between “date”-variables (month and year
of birth, death, last follow-up)
● counter variables for subsequent primary neoplasms
and cardiac events
● special checks (e.g. age range, identifying 5-year
survivors)
● checks on the ICD- and ICD-O-coding regarding causes
of death and coding diagnoses. Codes referring to
ICD7, 8, 9, and 10 have been accepted as well as codes
referring to ICD-O-1, -2 and -3 [e.g. 13–17].
● late mortality variables (e.g. cause of death is missing)
● data regarding second cancer (e.g. regarding ICD-O and
ICD-Code)
● cardiac variables (e.g. implausible or missing code of
the cardiac events)
To make the distribution of different childhood cancer
diagnoses comparable between the different DPs we
transformed the codes into International Classification of
Childhood Cancer. IARC/IACR Tools are available to
transfer ICD-O into ICD-O-2 and ICD-O-3 using a con-
version programme provided by the International Agency
for Research on Cancer (IARC) [18]. The transition from
ICD-O-2 to ICCC is going back on the IARC Child Check
Program published in International Classification of
Childhood Cancer (IARC Technical report No. 29, 1996).
The transfer of ICD-O to ICCC3 (International Classifi-
cation of Childhood Cancer, Third edition (ICCC-3) [19])
is adapted to this IARC Child Check Program and a long-
term used tool developed at the German Childhood Cancer
Registry, which we approved while transferring all ICD-O
codes to ICCC-3 codes to allow comparability with other
international sources at our registry.
There were some ICD-O-Codes included in ICD-O-1,
ICD-O-2, or ICD-O-3 but diagnoses are not defined in
ICCC-3. Those diagnoses are relevant diagnoses for pae-
diatric cancer in general but had to be categorized as
“further classifiable but non ICCC-3 diagnoses”, as they
were benign, not further classifiable, or in situ diagnoses (e.
g. Langerhans cell-histiocytosis, appendix carcinoid,
lipoma, schwannoma, cavernous haemangioma, haeman-
gioblastoma, ganglioneuroma, neurofibromatosis). As the
Norwegian data set is mainly based on ICD-7 we were not
able to transform these data sets into ICCC-3 appropriately
(“unclassifiable”).
Following validity checks WP1 asked DPs to clarify
identified implausibility (step 4) and to send a corrected
data set (step 5). As a final step overall summary reports
were used to discuss last remaining open issues with all
WP leaders. Once all these steps were completed WP1
assembled the PanCareSurFup cohort (step 6).
Results
Data provision and validity checks
Data sets came from the DPs in batches. In most cases they
came with updates to individual subjects. The plausibility
and validity checks and the resulting questions led, in total,
to more than 70 data sets delivered from the DPs to WP1,
including revisions and updates from the 13 DPs to WP1
(one DP sent data 20 times, the remaining 12 DPs sent data
6 to 9 times each). Data sets included a set of additional
patients or just single additional patients, event-specific
additional data, or corrected files due to erroneous data.
Simultaneously WP1 sent WP-specific cohort data 38 times
to the three outcome-related WPs: seven data deliveries to
two and 24 deliveries to the third one.
D. Grabow et al.
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Among others, the following challenges occurred when
checking the data which made further updates necessary:
● At the beginning of the cycles of plausibility checks
there were more errors regarding simpler procedures
like non-valid codes or incorrect time sequence.
● One DP at first provided data only for cases with an
event (cardiac disease, second cancer, late mortality)
but not for cases without any of these events. So data
from the entire cohort was requested and received.
● The most complex errors occurred when checking the
ICD- and ICD-O-coding. For example, ICD-O topog-
raphy codes normally start with a ‘C’, i.e. malignant
disease. A few codes sent started with a ‘D’ (non-
malignant). The discussion concerning this issue led to
the decision to include Langerhans cell-histiocytosis
though this is not coded as malignant.
In another case, one DP delivered a large number of
cases with unknown morphology and topography, respec-
tively, based on about 100 different self-defined codes.
Extensive discussion with the DP were required to discern
the meaning of these codes. In a next step these codes were
adapted, e.g. to ICD-O-2-topography. Many issues required
discussion of individual cases for resolution. Since this DP
had run out of resources, WP1 adapted the data for the DP.
The PanCareSurFup cohort
The overall cohort is described divided by different DPs
and with respect to length of follow-up and distribution of
sex, age and diagnostic groups: This data collection effort
formed the basis for WP3 to 5. Each DP included all ICCC-
3 diagnostic groups with the exception of France, where
only patients with solid tumours were reported. The year of
diagnosis varied widely (Table 2): three DPs started in the
1940s (France, Denmark, the UK), most started in the
1950s and 1960s. End of case assessment was between
1986 (France) and 2011 (Finland). The span of years of
diagnosis covered by the data from each DP varied
between 38 and 60 years with the widest span in Denmark
(1943–2003) and Finland (1953–2011). Figure 2 shows the
distribution of cases by year of diagnosis and by data
provider. Overall, most patients added to the
PanCareSurFup cohort were diagnosed in the 1980s and
1990s. Some DPs added about the same number of patients
each year (e.g. the Nordic Countries), while others (e.g.,
Italy, France and Hungary) provided more numbers in later
years.
The median observation time varied between 12 and
28 years (Table 2) (based on the late mortality cohort; for
the cardiac cohort and the second cancer cohort observa-
tion time was somewhat shorter). For the entire cohort the
Fig. 2 Number of cases in the PanCareSurFup 5-year survivor cohort by year of diagnosis and by data provider (based on 83,333 individuals as
specified in Table 3)
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median observation time was 16 years. Follow-up ended
for most DPs in the 2010s (latest follow-up year was 2015
for France), for some DPs follow-up ended at the beginning
of the 2000s (Table 2). For each DP more than half of the
patients were older than 23 years at date of latest follow-
up; for three DPs the median was more than 30 years. Some
DPs provided data sets in which more than 5% of the
individuals are older than 50 years at the latest follow up
(95% percentile). Of the 5-year survivor cohort with 83,333
individuals, the 50 and 95% percentile of age at latest
follow-up were 28 and 51 years, respectively.
The cohort of 5-year survivors as part
of the PanCareSurFup cohort
It was expected from the beginning that the main part of
the entire cohort would be the 5-year survivor cohort,
described in Table 3. However, where possible, DPs were
asked to provide data on their entire cohorts (i.e. all cases
registered irrespective of the follow-up time). Several DPs
provided only 5-year survivors (France, Hungary, The
Netherlands, Switzerland and the UK). Others provided
cohorts which included patients from the date of diagnosis
(Nordic countries, Slovenia and Italy population based),
while Italy hospital-based included only patients who had
reached the elective end of therapy (off therapy), regardless
of its timing with respect to the date of diagnosis. Totally,
83,333 5-year survivors were reported. Together with
reported patients followed up less than 5 years (i.e. 32,263
individuals) the cohort sums up to a cohort of 115,596
patients. In the 5-year survivor cohort of 83,333 individu-
als, the UK and the Italian hospital-based cohort con-
tributed more than 10,000 cases, five others contributed
between 5,000 and 10,000 cases. The median follow-up
time for the 5-year survivor cohort was 20 years, ranging
from 12 to 28 years.
The three outcome-specific cohorts were based on the
5-year survivor cohort, as follows:
● For cardiac events (WP3) data from eight DPs were
collected. Among 39,152 survivors, 1014 experienced
cardiac events. Most individuals with at least one event
were reported from the UK (446 patients with at least
one cardiac event), France (192), and the Netherlands
(176) with the remaining DPs each providing fewer
than 100 cases.
Table 3 Size of PanCareSurFup (PCSF) cohort and outcome specific cohorts with number of events by data provider
Country Total number of
patients included in
PCSF cohort
Outcome specific 5-year survivor cohortsa
Cardiac cohort Second cancer cohort Late mortality cohort
Entire
cohort
5-Year
survivor
cohort
No. of
patients in
cardiac
cohort
No. of patients
with at least one
cardiac event
No. of patients
in second
cancer cohort
No. of patients
with at least one
second cancer
No. of patients
in late
mortality
cohort
No. of
deceased
patients
1 France 3171 3146 3146 192 3157 419 3146 757
2 Hungary 5167 5142 4907 71 4920 160 5142 441
3 Italy—pop.b 15,124 9477 1554 57 8117 262 9477 555
4 Italy—hosp.c 12,315 11,051 1576 21 1576 123 11,051 976
5 The
Netherlands
6087 6087 5189 176 6087 352 6087 617
6 Denmark 12,099 4822 – – 4966 306 4822 589
7 Sweden 15,180 9302 – – 8348 373 9302 863
8 Norway 8562 3892 – – 3892 108 – –
9 Finland 12,243 6341 – – 6341 401 6341 855
10 Iceland 609 351 – – 302 10 351 34
11 Slovenia 2341 1258 1155 21 1259 115 1258 179
12 Switzerland 4717 4483 3645 30 4549 144 4483 332
13 UK 17,981 17,981 17,980 446 17,980 1222 17,981 3049
Total 115,596d 83,333 39,152 1014 71,494 3995 79,441 9247
a For each cohort calculated on the basis of the respective date of follow-up, but including the death date from the late mortality cohort
b Pop. = population-based
c Hosp. = hospital-based
d A thorough investigation by WP4 of the SPN component of the entire cohort (n = 115,596) resulted in an agreed denominator of 105,015
individuals to enter into the SPN analyses
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● For second cancers (WP4) every DP was able to
contribute data. Among 71,494 5-year survivors 3995
individuals developed at least one second cancer during
the reporting period. Most individuals were reported
from the UK (1222 patients with at least one second
cancer), France (419), and Finland (401).
● For the late mortality cohort, data from all DPs besides
Norway were available. This resulted in the cohort of
79,441 individuals of whom 9247 were deceased. Most
patients deceased were reported from the UK (3049),
Italy (hospital-based) (976), Sweden (863), and Finland
(855).
Table 4 PanCareSurFup (PCSF) 5-year survivor cohort by age at diagnosis and data provider
No. of 5-year
survivors PCSF
cohort
Age at diagnosis Sex ratio at time
of diagnosis
(male/female)0–14 years
N (%)
15–17 years
N (%)
18–20 years
N (%)
France 3146 2988 (95) 155 (4.9) 3 (0.1) 1.2
Hungary 5142 4613 (89.7) 469 (9.1) 60 (11.7) 1.3
Italy—pop.a 9477 6420 (67.7) 1456 (15.4) 1601 (16.9) 1.2
Italy—hosp.b 11,051 10,468 (94.7) 496 (4.5) 87 (0.8) 1.2
The Netherlands 6087 5565 (91.4) 489 (8.0) 33 (5.4) 1.3
Denmark 4822 3112 (64.5) 796 (16.5) 914 (19.0) 1.3
Sweden 9302 6117 (65.8) 1545 (16.6) 1640 (17.6) 1.1
Norway 3892 2441 (62.7) 636 (16.3) 815 (20.9) 1.1
Finland 6341 4158 (65.6) 1060 (16.7) 1123 (17.7) 1.0
Iceland 351 212 (60.4) 65 (18.5) 74 (21.1) 1.1
Slovenia 1258 1009 (80.2) 249 (19.8) 0 (0) 1.2
Switzerland 4483 3500 (78.1) 552 (12.3) 431 (9.6) 1.3
UK 17,981 17,450 (97.0) 531 (3.0) 0 (0) 1.2
Total 83,333 68,053 (81.7%) 8499 (10.2%) 6781 (8.1%)
a Pop. = population-based
b Hosp. = hospital-based
Table 5 PanCareSurFup
(PCSF) 5-year survivor cohort
by provided classification and
data provider
ICD-7-Codinga ICD-O-1b ICD-O-2b ICD-O-3b Total
France 0 2084 1062 0 3146
Hungary 0 0 0 5142 5142
Italy—pop.c 0 0 0 9477 9477
Italy—hosp.d 0 0 0 11,051 11,051
The Netherlands 0 0 0 6087 6087
Denmark 0 4822 0 0 4822
Sweden 0 0 9291 11 9302
Norway 3103 0 789 0 3892
Finland 0 0 0 6341 6341
Iceland 0 0 0 351 351
Slovenia 0 0 0 1258 1258
Switzerland 0 0 0 4483 4483
UK 0 0 0 17,981 17,981
Total 3103 6906 11,142 62,182 83,333
a ICD-7 = International Classification of Diseases, Revision 7
b ICD-O = International Classification of Diseases for Oncology, Version 1, 2, 3
c Pop. = population-based
d Hosp. = hospital-based
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Table 6 PanCareSurFup (PCSF) 5-year survivor cohort transformed to ICCC-3adiagnostic group by data provider
No. of 5-year
survivors
PCSF cohort
N (%)
Group of diagnosis
I
Leukemias
N (%)
II
Lymphomas
N (%)
III
Tumors of the
central nervous
system
N (%)
IV
Neuro-
blastoma
N (%)
V
Retino-
blastoma
N (%)
VI
Renal
tumors
N (%)
1 France 3146 – 560 (17.8) 438 (13.9) 425 (13.5) 146 (4.6) 639 (20.3)
2 Hungary 5142 1515 (29.5) 832 (16.2) 1048 (20.4) 383 (7.5) 128 (2.5) 360 (7.0)
3 Italy—pop.d 9477 2188 (23.1) 1961 (20.7) 1570 (16.6) 415 (4.4) 176 (1.9) 370 (3.9)
4 Italy—hosp.e 11,051 4591 (41.5) 1966 (17.8) 752 (6.8) 985 (8.9) 85 (0.8) 938 (8.5)
5 The Netherlands 6087 2094 (34.4) 983 (16.2) 842 (13.8) 324 (5.3) 33 (0.5) 596 (9.8)
6 Denmark 4822 912 (18.9) 692 (14.4) 1144 (23.7) 145 (3.0) 175 (3.6) 226 (4.7)
7 Sweden 9302 1640 (17.6) 1183 (12.7) 2253 (24.2) 205 (2.2) 252 (2.7) 448 (4.8)
8 Norway 3892 – 2 (0.1) 150 (3.9) 22 (0.6) 24 (0.6) 30 (0.8)
9 Finland 6341 1297 (20.5) 1023 (16.1) 1333 (21.0) 222 (3.5) 176 (2.8) 314 (5.0)
10 Iceland 351 60 (17.1) 51 (14.5) 65 (18.5) 9 (2.6) 6 (1.7) 14 (4.0)
11 Slovenia 1258 279 (22.2) 246 (19.6) 232 (18.4) 36 (2.9) 34 (2.7) 80 (6.4)
12 Switzerland 4483 1280 (28.6) 777 (17.3) 713 (15.9) 205 (4.6) 115 (2.6) 220 (4.9)
13 UK 17,981 4851 (27.0) 2307 (12.8) 4111 (22.9) 792 (4.4) 1200 (6.7) 1505 (8.4)
Total 83,333 20,707 (24.9) 12,583 (15.1) 14,651 (17.6) 4168 (5.0) 2550 (3.1) 5740 (6.9)
ACCIS Data for comparison [16] 77,111 26,690 (34.6) 8971 (11.6) 17,057 (22.1) 5580 (7.2) 1995 (2.6) 4549 (5.9)
Group of diagnosis
VII
Hepatic
tumors
N (%)
VIII
Malignant
bone tumors
N (%)
IX
Soft tissue
sarcomas
N (%)
X
Germ cell
tumors
N (%)
XI
Other malignant
epithelial
neoplasms
N (%)
XII
Other
malignant
neoplasms
N (%)
Otherb: e.g.
LCHc
N (%)
Unclassifiable
N (%)
1 France 28 (0.9) 228 (7.3) 356 (11.3) 178 (5.7) 113 (3.6) 8 (0.3) 10 (0.3) 17 (0.5)
2 Hungary 50 (1.0) 259 (5.0) 261 (5.1) 146 (2.8) 106 (2.1) 10 (0.2) 32 (0.6) 12 (0.2)
3 Italy—pop.d 50 (0.5) 385 (4.1) 497 (5.2) 527 (5.6) 832 (8.8) 122 (1.3) 378 (4.0) 6 (0.1)
4 Italy—hosp.e 65 (0.6) 285 (2.6) 623 (5.6) 238 (2.2) 78 (0.7) 26 (0.2) 417 (3.8) 2 (0.0)
5 The Netherlands 52 (0.9) 369 (6.1) 451 (7.4) 231 (3.8) 98 (1.6) 7 (0.1) 3 (0.1) 4 (0.1)
6 Denmark 19 (0.4) 160 (3.3) 278 (5.8) 436 (9.0) 484 (10.0) 43 (0.9) 71 (1.5) 37 (0.8)
7 Sweden 61 (0.7) 371 (4.0) 497 (5.3) 551 (5.9) 899 (9.7) 327 (3.5) 614 (6.6) 1 (0.0)
8 Norway 12 (0.3) 36 (0.9) 45 (1.2) 61 (1.6) 75 (1.9) 7 (0.2) 39 (1.0) 3389 (87.1)
9 Finland 33 (0.5) 265 (4.2) 384 (6.1) 342 (5.4) 784 (12.4) 59 (0.9) 107 (1.0) 2 (0.0)
10 Iceland 2 (0.6) 17 (4.8) 23 (6.7) 22 (6.3) 46 (13.1) 1 (0.3) 28 (8.0) 7 (2.0)
11 Slovenia 6 (0.5) 56 (4.5) 91 (7.2) 68 (5.4) 92 (7.3) 3 (0.2) 7 (0.6) 28 (2.2)
12 Switzerland 32 (0.7) 211 (4.7) 268 (6.0) 232 (5.2) 270 (6.0) 11 (0.3) 149 (3.3) 0 (0)
13 UK 65 (0.4) 664 (3.7) 1180 (6.7) 638 (3.4) 614 (3.4) 43 (0.2) 7 (0.0) 4 (0.0)
Total 475 (0.6) 3306 (4.0) 4954 (5.9) 3670 (4.4) 4491 (5.4) 667 (0.8) 1862 (2.2) 3509 (4.2)
ACCIS Data for
comparison [16]
749 (1.0) 3692 (4.8) 5111 (6.6) 2555 (3.3) 1874 (2.4) 339 (0.4) – –
a International Classification of Childhood Cancer, Third edition [14]
b Other further classifiable diagnoses: defined in ICD-O, but not in ICCC-3
c LCH = Langerhans cell-hystiocytosis
d Pop. = population-based
e Hosp. = hospital-based
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Tables 4–6 describe the cohort of 83,333 5-year sur-
vivors by sex, age, and diagnoses. Sex ratios showed the
expected male predominance with little variability
(Table 4). The distribution by age at diagnosis varied as
some country specific cohorts covered mostly children up
to 14 years, while others covered cancer cases up to
20 years. Table 5 shows which diagnostic codes were used
in the different DPs specific cohorts. Nine DPs coded
diagnoses for all patients by using solely ICD-O-3 as the
most current version of ICD-O. The others used older
editions of ICD-O: France coded with ICD-O-1 as well as
with ICD-O-2. Denmark and Sweden used ICD-O-1 or
ICD-O-2, respectively. For the majority of cases in the
Norwegian cohort only ICD7 was reported. Table 6 shows
the distribution of cases by ICCC-3 diagnostic groups for
each DP. For the sake of comparability with data from
European population-based cancer registries, we included
the distribution of the twelve corresponding diagnostic
groups reported from ACCIS (Automated Childhood
Cancer Information System project) in this table [20].
Discussion
The aim of WP1 in the PanCareSurFup project was to
amalgamate data of survivors after childhood cancer from
European cancer registries and other databases which were
available for the three outcomes relevant to PanCare-
SurFup (cardiac events, second cancer, late mortality).
Based on this, clinical epidemiological studies were carried
out on a selected set of serious late effects.
Through the cooperation of 16 project partners and 13
DPs from 12 countries, the project succeeded in generating
the largest cohort of children with cancer in Europe to date.
The resulting cohort of 83,333 5-year survivors is unique
due to its size and the collection of a selected set of late
effects. Additionally 32,263 non-five year survivors were
collected, resulting in a cohort of 115,596 individuals. It
provides an excellent opportunity to compare each decade
since the 1940 with respect to childhood cancer and allows
for a good comparison of survival rates.
Compared to other population-based European data
collections, like ACCIS [1, 20, 21], some diagnoses differ
in numbers, but the overall distribution in the PCSF cohort
corresponds with the ACCIS data. While considering that
variety of diagnoses in different countries is not uncommon
to a certain extent [22] only few deviations can be seen in
Table 6, primarily caused by the two further classification
groups we implemented (“other further classifiable” like
Langerhans cell-histiocytosis and “unclassifiable” with
respect to ICCC-3). Furthermore, we have to take into
account that we cannot entirely compare those two
resources as ACCIS collects data since diagnosis, and our
cohort is based on 5-year survivors, i.e. starts 5 years after
diagnosis. Diagnoses with poorer survival (e.g. CNS
tumours) were underrepresented compared to incidence
data at time of diagnosis. Additionally, due to the fact that
France delivered a cohort without leukaemia patients, this
group contributes a little bit less than about a third to the
data. Further on we seem to have a slight underreporting
regarding tumours of the central nervous system (CNS),
which is a known phenomenon as this diagnostic group
with its different histology and behaviour is heteroge-
neously collected in cancer registries [23]. Neuroblastoma
are somewhat less and lymphomas are somewhat more
frequent compared to ACCIS. Regarding quality indicators,
almost all of the data sources included in PanCareSurFup
contributed as well to ACCIS, where no substantial dif-
ference between quality indicators was seen for the dif-
ferent data providers [24].
The assembled PanCareSurFup cohort is characterised
by inclusion of all malignant diseases occurring from 0 to
20 years of age, with the exceptions previously mentioned.
It should particularly be pointed out that the three outcomes
relevant to PanCareSurFup are being investigated in
approximately the same basic population. While cancer
registries routinely collect mortality and second cancer
incidence, other outcomes, such as cardiac disease, is not
routine. In PCSF a small number of DPs were able to
collect cardiac morbidity.
The project includes all DPs which were identified by a
preceding survey and fulfil relevant requirements (e.g.
good quality of follow-up, availability of relevant infor-
mation, legal and organisational prerequisites). Thus, data
are often collected through a population-based cancer
registry, through a body with close connection to a popu-
lation-based cancer registry, or within a clinical registry. In
the future, statements largely representative of the popu-
lation will be possible based on these analyses. Some
countries that would have participated could not provide
data for a variety of reasons. First, in some countries
information on these outcomes was not centrally available;
in other countries retrieving therapy data from clinical
sources was not possible, and finally some potential DPs
were uncertain that the data could be provided within the
project period. The Nordic countries could not provide
cardiac events due to the ongoing parallel Nordic study
ALiCCS [25].
The cohort is based on data sets which were collected in
very different contexts. For example, the Nordic countries
had already established population-based cancer registries
with high data quality and high completeness in the middle
of the last century. However they lack precise information
on treatment. Other countries, e.g., in Eastern Europe, also
have long-standing data collections, not previously con-
tributed to bigger projects. The persons responsible had
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very diverse backgrounds (epidemiologists, clinicians,
registry experts) with different technical equipment and
experience. DPs who were less experienced in delivering
data to huge consortia received assistance from WP1 to
deliver data which met the characteristics of the PCSF
baseline variable list. Additionally, differences in back-
ground and level of experience were ironed out through
regular meetings and bi-weekly conference calls. The use
of a common data structure reduced differences between
data sources.
The homogeneity of the PCSF cohort data was ensured
by the following procedures: The creation of a common
baseline variable list, standardised data flow and uniform
data sets. All WP leaders early on determined the extent
and content of the characteristics, the naming of variables,
and the coding. The technical procedure of the transfer of
encrypted data and the schedule for data delivery were also
fixed. The call-for-data, i.e., the starting point for data
delivery by the DP, included all these specifications. The
harmonisation contained technical validity checks, plausi-
bility checks, and further consultations with the DPs if
there were implausibility or technical problems. For bigger
plausibility problems, single new transfers of “corrected”
data packages were also scheduled. The use of self-gen-
erated codes which are not defined in international diag-
nostic classifications in some cancer registries is an
example to show that it makes sense to carry out basic
validity checks centrally.
The basic principle of this project, namely that the
cohort data of the single DPs were sent to a data centre
(WP1) instead of three outcome-related WPs, proved suc-
cessful: WP1 was responsible for carrying out validity
checks of all variables which did not refer to the outcome
relevant characteristics. Otherwise, each WP would have
needed to come up with and could have realised its own
solution, and the data sets would not have been compara-
ble. So all WPs profited from this procedure. The WPs with
additional case–control designs had to set up further
specific procedures for additional case–control-related
treatment data, which were collected by WP3 and WP4
separately.
However, in general it was the responsibility of the
respective WP leaders with their specific know-how to
decide upon the outcome-specific variables (e.g., to decide
which events were ultimately classified as cardiac events).
While inquiries to the DPs were carried out solely via WP1
in the beginning, implausibility in outcome-specific vari-
ables were arranged to be clarified directly with the
responsible WP leaders for the remainder of the project
duration. Within the scope of the case–control study con-
ducted, DPs had to be contacted on the part of WP3 and
WP4 (e.g., for assigning controls to cases or for providing
therapy data for cases and controls which had not been
provided for in the superordinate data set). Due to the
amalgamation of the data by a central office and the
plausibility checks carried out by these two levels, we can
assume high data quality.
Despite the basically unambiguous rules, a number of
obstacles occurred, which required complex solutions.
These solutions were necessary in order to generate a
harmonised, large, and meaningful cohort. Basically, can-
cer registries are dynamic data sources, in which older data
may be modified (subsequent changes, e.g., of diagnosis or
age can be seen from time to time) and follow-up infor-
mation becomes more current the longer the follow-up
duration. Therefore, it is recommended that the DPs freeze
their data on a specified day and provide them for the
overall project. This was, however, hard to communicate,
and some DPs kept transferring modified data sets to WP1.
This is acceptable in some degree if this leads to a con-
siderably improved data quality. However, marginal
changes should not result in new update deliveries. It
proved to be difficult to find the right balance.
Limitations of the assembling of this huge retrospective
European cohort are that DPs were not always able to
provide data as specified in the call-for-data; instead,
individual arrangements concerning the data delivery and
an adjustment of the central WP1 data base to individual
import strategies became necessary. In the end, an indi-
vidual handling for almost each DP was necessary. This
caused temporal delays and the risk was real that some
outcome-related WPs would fall behind; as a result, some
DPs delivered their data prematurely and multiple times via
WP1 to WP leaders, even though data entry and data
processing had not been completed. For this reason, many
more data updates than intended had to be accepted. The
following example demonstrates the complexity: One DP
provided 20 data updates altogether, and one WP received
24 data transfers from WP1. In principle, updates were
planned only as an exception (step 5 in Fig. 1), and only
one single data transfer from WP1 to the respective out-
come-related WPs was planned (step 7). In addition, the
progress of the work packages went in parallel. However,
this could be balanced and compensated by WP1, while
three independent, parallel work packages would have been
hard to coordinate. Some DPs did not provide data for all
three outcomes. In part, this was planned from the begin-
ning (e.g., no cardiac events from the Nordic countries), in
part, it became apparent only during the project duration
that data could not be provided (e.g. mortality data from
Norway are in general available, but could not be provided
within the scope of this project). The duration of obser-
vation differed for the single events among the data sets of
some DPs (e.g., longer duration for cardiac events than for
the occurrence of second tumours).
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In order to make the ultimate cohort centrally available
after the end of the project, the data bases of WP3-5 will
finally be transferred to WP1 again. WP1 will store the data
and make them available for future projects, should the
occasion arise. The cohorts finally analysed in the work
packages (e.g. as basis for case–control studies) will differ
from the cohort described here due to WP-specific eligi-
bility criteria. Nevertheless, the PCSF cohort described is
the basis for all analyses to be carried out in PanCare-
SurFup as well as for projects going beyond the end of the
project.
In a consortium like this one, progress largely depends
on iron discipline and rigour with respect to the common
rules for project management. All partners must follow the
specifications of the consortium (deadlines, agreements,
definitions). As a basic principle, a transparent, prompt,
and problem-oriented communication is a necessary basis
for the success of such a complex project. Within the
course of the project, these processes proceeded more and
more smoothly.
Limitations of the consortium are that assembling a huge
cohort like this takes a lot of time and this took in the end
much longer than anticipated from the beginning. PCSF
applied for and was granted a 1-year no-cost extension.
Data assembled many decades ago were difficult to collect
in some countries. Data management, databases, and data
differed from country to country mainly due to different
ways of collecting the cancer data and the outcomes,
requiring major efforts to make the data homogeneous and
comparable.
There are some lessons learned and ways to overcome
problems during the implementation of such a diverse
cohort to be composed by bringing together very different
data sets from different countries. It is strongly recom-
mended that one central institution is installed for doing all
the work regarding harmonization, standardization and
communication. An iron discipline has to be conformed as
well as rigour with respect to the common rules for project
management. A transparent, prompt and problem-oriented
communication is needed, too. The involved parties should
find the right balance between being adamant about stan-
dardized procedures while on the other hand considering
individual country-specific and data provider-specific
framework conditions. Regarding the practical approach
data providers should freeze their relevant data set on a
specific day and avoid updates with only marginal modi-
fications. The ultimate cohorts should be made centrally
available at the end of the project by each work package
leader and should have backups to enable sustainability and
long-lasting data security.
Benefits of the consortium assembling late effects data is
that rare late effects detected in more countries can be
pooled and this might lead to new strategies for identifying
ways to treat late effects and reach best clinical follow up.
The assembled cohort is the largest cohort in Europe and
under a handful others under the largest worldwide.
Amalgamations of this kind enable analyses which would
not have been possible because the diseases are so rare.
The scientific legacy produced by PanCareSurFup is
available for maintenance, update, and future use in
accordance with the regulations set up after the official
funding end of the project. Therefore, a PanCareSurFup
Sustainability, Publication and Authorship Policy has been
developed, which includes that requests from outside
investigators for use of the PCSF data will be welcome at
least 5 years from the end of the study. The final datasets
from each work package of PanCareSurFup are stored at
the original work package leader’s institution. Back-ups of
all data are stored at defined other institutions.
PanCareSurFup succeeded in compiling the largest and
in itself homogeneous cohort of children with cancer dur-
ing childhood and adolescence through the close coopera-
tion of many European countries and by establishing a
work package solely for the harmonisation of heteroge-
neous data sources. We can expect high quality results
analysing this large data set with respect to the three out-
comes in PanCareSurFup. The resulting data set provides
an excellent opportunity to compare outcomes of patients
diagnosed over seven decades.
Depending on the national situation per data provider,
informed consent was obtained from all individual partic-
ipants included in the study, or the data collection was done
under national law. All data providers obtained ethical
approval or approval from the relevant national body, and
PanCareSurFup was supervised by the PCSF Ethical and
Scientific Advisory Board.
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